Results 121 to 130 of about 119,519 (336)

Janus kinase inhibitor audit

Clinical Medicine, 2023
Beck, Jenni, Banford, Samantha
openaire   +2 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

, 2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources

Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study

, 2023
Lieke E.J.M. Scheepers, Yifei Yang, Yi Lung Chen, Graeme Jones   +3 more
openalex   +1 more source

A cooperative release of mitochondrial DNA from platelets and neutrophils drives an interferon signature in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis, André N. Tiaden, Simone Häner‐Massimi, Diego Kyburz, Cedric André, Anton Glück, Enrico Ferrero, Stuart Hawtin, Tobias Junt, Ulrich A. Walker   +9 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor [PDF]

, 2022
Reid A. Waldman, Kelley Sharp, Jónas A. Aðalsteinsson, Jane M. Grant‐Kels   +3 more
openalex   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Exosome as bioactive nanovesicle for diagnostic and therapeutic applications in periodontitis

BMEMat, EarlyView.
This review introduces the mechanism that exosomes participate in the pathogenesis of periodontitis and their potential as biomarkers for early diagnosis and summarizes the application of cell‐ or plant‐derived exosomes or engineered exosomes in periodontitis or periodontal regeneration while proposing the perspective of translational application of ...
Yu Wang, Yuchen Li, Yunfan Zhang, Chenshuang Li, Yifan Lin, Si Chen, Bing Han   +6 more
wiley   +1 more source

Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients

Iraqi Journal of Hematology
BACKGROUND: Diagnosis of myeloproliferative neoplasms including polycythemia vera (PV) has been greatly improved following the identification of driver mutations at exon 12 and exon 14 of the Janus Kinase 2 (JAK2) gene. There are limited academic studies
Mushtaq M. Khazeem, Alaa Fadhil Alwan
doaj   +1 more source

Role of Janus kinase-2 in insulin-mediated phosphorylation and inactivation of protein phosphatase-2A and its impact on upstream insulin signalling components [PDF]

, 1999
Najma BEGUM, Louis Ragolia
openalex   +1 more source